Brachytherapy News and Research RSS Feed - Brachytherapy News and Research

Brachytherapy is a minimally invasive procedure that involves the use of radioactive seeds the size of rice grains. Brachytherapy, an out-patient procedure, usually takes 45 minutes to an hour to perform. Most patients can return to their normal activities within days. The success rates of prostate brachytherapy have compared favorably with success rates of radical prostatectomy and external beam radiation. In comparison studies, prostate brachytherapy has shown to have a favorable side effect profile when compared with other modalities. Clinical studies have shown that prostate brachytherapy has a cure rate of 94% for appropriately selected patients.
BioZorb 3D surgical marker improves ability to target radiation treatment for breast cancer

BioZorb 3D surgical marker improves ability to target radiation treatment for breast cancer

The BioZorb™ three-dimensional surgical marker improved the ability of radiation oncologists to target radiation treatment for breast cancer, according to a scientific presentation at the 2014 American Brachytherapy Society (ABS) Annual Meeting. [More]
ASTRO white paper recommends specific guidance to follow in the delivery of HDR brachytherapy

ASTRO white paper recommends specific guidance to follow in the delivery of HDR brachytherapy

The American Society for Radiation Oncology has issued a new white paper, "A review of safety, quality management, and practice guidelines for high-dose-rate brachytherapy," that recommends specific guidance to follow in the delivery of high-dose-rate (HDR) brachytherapy to improve quality and patient safety, according to the manuscript published in the March-April 2014 print issue of Practical Radiation Oncology, the official clinical practice journal of ASTRO. [More]
Yangon General Hospital first to install Varian technology for cancer treatment

Yangon General Hospital first to install Varian technology for cancer treatment

Yangon General Hospital has become the first clinical site in Myanmar to install new technology from Varian Medical Systems (NYSE: VAR) for treating cancer with radiotherapy. [More]

AMIC provides report on FDA pre-market notification related to brachytherapy cancer product

Advanced Medical Isotope Corporation ("AMIC"), a company engaged in the development, production and distribution of medical isotopes focused on yttrium-90 brachytherapy devices, today announced that it has received a response from the FDA to its pre-market notification to the FDA pursuant to Section 510(k) of the U.S. Food, Drug and Cosmetic Act for its Yttrium-90 (Y-90) RadioGel(tm) patented brachytherapy cancer product. [More]
iCAD total revenue for Q4 2013 increases 16.8% to $9.1 million

iCAD total revenue for Q4 2013 increases 16.8% to $9.1 million

iCAD, Inc., an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today reported financial results for the three and twelve months ended December 31, 2013. [More]
Researchers offer new options for men whose prostate cancer has spread to bones

Researchers offer new options for men whose prostate cancer has spread to bones

Dartmouth-Hitchcock Norris Cotton Cancer Center has treated three men with a recently FDA-approved treatment, which offers new options for men whose prostate cancer has spread to their bones. [More]

Patients receiving APBI after breast-conserving surgery show excellent tumor control, breast cosmesis

Long-term outcomes of breast cancer patients receiving adjuvant accelerated partial breast irradiation after breast-conserving surgery show excellent tumor control and breast cosmesis (cosmetic outcomes) with minimal late toxicity, according to a study published in the February 1, 2014 print edition of the International Journal of Radiation Oncology. [More]

EBRT provides higher breast preservation rate in women with invasive breast cancer

Standard external beam radiation therapy (EBRT) provided a higher breast preservation rate than brachytherapy in women age 66 and older with invasive breast cancer, according to a study published in the February 1, 2014 print edition of the International Journal of Radiation Oncology ● Biology ● Physics (Red Journal), the official scientific journal of the American Society for Radiation Oncology (ASTRO). [More]
Prostate cancer patients treated with ADT experience mental, emotional well-being during treatment

Prostate cancer patients treated with ADT experience mental, emotional well-being during treatment

​A new study published in the Journal of Urology- reports that prostate cancer patients treated with androgen deprivation therapy (ADT) experienced changes in mental and emotional well-being during treatment, although there was no meaningful decline in emotional quality of life two years after treatment. [More]

Varian Medical Systems' updated ProBeam proton therapy system gets FDA clearance

Varian Medical Systems has received FDA 510(k) clearance for its updated ProBeam proton therapy system. [More]
China's Health Department of the People's Liberation Army orders clinical solutions from Elekta

China's Health Department of the People's Liberation Army orders clinical solutions from Elekta

To help manage the growing incidence of cancer, China's Health Department of the People's Liberation Army has ordered a comprehensive range of clinical solutions from Elekta. Fourteen hospitals around the country will receive in total 15 linear accelerators (linacs). [More]

Elekta to launch MOSAIQ oncology information system throughout McLaren's cancer network

The ability to effectively manage data across disparate health systems to help drive quality care will be a cornerstone for health systems of the future. Elekta is proud to announce today that it has joined forces with Michigan-based McLaren Health Care to launch MOSAIQ oncology information system throughout McLaren's cancer network. [More]

Elekta and McLaren Health Care to launch MOSAIQ oncology information system

The ability to effectively manage data across disparate health systems to help drive quality care will be a cornerstone for health systems of the future. Elekta is proud to announce today that it has joined forces with Michigan-based McLaren Health Care to launch MOSAIQ® oncology information system throughout McLaren's cancer network. [More]

Nucletron installs first Esteya electronic brachytherapy system for skin cancer treatment

The first Esteya electronic brachytherapy system in the United States has been installed at New York's Memorial Sloan-Kettering Cancer Center. Esteya by Nucletron, an Elekta company, is a new approach for skin cancer treatment that relies on a small, high dose rate (HDR) X-ray source to apply high precision radiotherapy directly to the cancer site. [More]
Experts develop innovative technologies to improve healthcare and border security

Experts develop innovative technologies to improve healthcare and border security

With a solemn ceremony organized on December 11, 2013 NCBJ concluded the 85.5 million PLN worth "AiD" R&D project co-financed by European Union. Project outcomes include 3 demonstrators of innovative medical devices (Coline 6, IntraLine, and InLine PN50) and 2 demonstrators of cargo scanners developed to improve security at European border crossing checkpoints (SWAN and CANIS). [More]

C4 Imaging receives FDA clearance for Sirius MRI Marker

C4 Imaging LLC is pleased to announce U.S. Food and Drug Administration 510(k) clearance of its first product, the Sirius™ MRI Marker. The novel Positive-Signal MRI Marker will be used following treatment of prostate cancer with brachytherapy to facilitate seed localization within the prostate, utilizing a single post-implant Magnetic Resonance imaging procedure. [More]
Advanced prostate cancer therapies: an interview with Dr. Nancy Dawson, Lombardi Comprehensive Cancer Center

Advanced prostate cancer therapies: an interview with Dr. Nancy Dawson, Lombardi Comprehensive Cancer Center

The prostate gland produces part of the seminal fluid that protects sperm. It is located in front of the rectum and under the bladder, and surrounds the urethra, the tube through which urine flows from the bladder to and out of the penis. [More]

Financial interests ‘driving IMRT uptake for prostate cancer’

A study suggests that the recent rapid uptake of intensity-modulated radiotherapy for prostate cancer in the USA has been driven by urologists with financial conflicts of interest. [More]
Nanomedicine Award winners officially announced at BIO-Europe conference

Nanomedicine Award winners officially announced at BIO-Europe conference

The winners of the first ever Nanomedicine Award were officially announced during the Nanomedicine Panel at BIO-Europe conference in Vienna, November 4th 2013. The Award review Board agreed to distinguish two projects in two different categories: The winners are Endomagnetics Ltd in the nanodiagnostic category and the I-CARE project from Linköping University in the regenerative medicine category. [More]

Men treated by self-referring urologists more likely to undergo unnecessary IMRT

A comprehensive review of Medicare claims for more than 45,000 patients from 2005 through 2010 found that nearly all of the 146 percent increase in intensity-modulated radiation therapy (IMRT) for prostate cancer among urologists with an ownership interest in the treatment was due to self-referral, according to new research, "Urologists' Use of Intensity-Modulated Radiation Therapy for Prostate Cancer," released today in The New England Journal of Medicine (NEJM) for its October 24, 2013 issue. [More]